Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MEDI-1814 by AstraZeneca for Alzheimer's Disease: Likelihood of Approval
MEDI-1814 is under clinical development by AstraZeneca and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase I...
Acalabrutinib maleate by AstraZeneca for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Acalabrutinib maleate by AstraZeneca for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According...
Acalabrutinib maleate by AstraZeneca for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...
Benralizumab by AstraZeneca for Rhinosinusitis: Likelihood of Approval
Benralizumab is under clinical development by AstraZeneca and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs...
TBO-309 by AstraZeneca for Acute Ischemic Stroke: Likelihood of Approval
TBO-309 is under clinical development by AstraZeneca and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase...
AZD-0780 by AstraZeneca for Cardiovascular Disease: Likelihood of Approval
AZD-0780 is under clinical development by AstraZeneca and currently in Phase I for Cardiovascular Disease. According to GlobalData, Phase I...
Durvalumab by AstraZeneca for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Durvalumab by AstraZeneca for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Extrahepatic Bile Duct Cancer. According to GlobalData,...
Capivasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Capivasertib is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Olaparib by AstraZeneca for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Olaparib is under clinical development by AstraZeneca and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
MEDI-7352 by AstraZeneca for Diabetic Neuropathic Pain: Likelihood of Approval
MEDI-7352 is under clinical development by AstraZeneca and currently in Phase II for Diabetic Neuropathic Pain. According to GlobalData, Phase...
Adavosertib by AstraZeneca for Laryngeal Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Adavosertib by AstraZeneca for Oropharyngeal Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Oleclumab by AstraZeneca for Solid Tumor: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Adavosertib by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Gefurulimab?
Gefurulimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Myasthenia Gravis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Datopotamab deruxtecan?
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Pre-Registration program in Non-Small Cell Lung Cancer....
Risk adjusted net present value: What is the current valuation of AstraZeneca's Volrustomig?
Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Cervical Cancer. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's MEDI-7352?
MEDI-7352 is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Diabetic Neuropathic Pain. According to...